Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management.


Journal

Chemotherapy
ISSN: 1421-9794
Titre abrégé: Chemotherapy
Pays: Switzerland
ID NLM: 0144731

Informations de publication

Date de publication:
2022
Historique:
received: 22 11 2021
accepted: 22 12 2021
pubmed: 3 1 2022
medline: 24 8 2022
entrez: 2 1 2022
Statut: ppublish

Résumé

Sarcopenia is almost constantly observed in patients with cirrhosis and hepatocellular carcinoma (HCC). Chronic liver disease represents a unique pathophysiological scenario in which sarcopenia develops and all factors involved in the pathogenesis should be taken into account for an appropriate management of the disease. No properly designed intervention studies on this topic are available and, thus, no effective strategies have been developed for clinical practice. Apart from any targeted intervention, treatment, and optimization of liver disease is crucial. In patients with cirrhosis and HCC, nutritional support to maintain and restore nutrition status, a targeted use of branched-chain amino acids and a guided physical exercise, should all be an integral part of the multidimensional assessment and tailored interventions.

Sections du résumé

BACKGROUND BACKGROUND
Sarcopenia is almost constantly observed in patients with cirrhosis and hepatocellular carcinoma (HCC).
SUMMARY CONCLUSIONS
Chronic liver disease represents a unique pathophysiological scenario in which sarcopenia develops and all factors involved in the pathogenesis should be taken into account for an appropriate management of the disease. No properly designed intervention studies on this topic are available and, thus, no effective strategies have been developed for clinical practice. Apart from any targeted intervention, treatment, and optimization of liver disease is crucial.
KEY MESSAGES CONCLUSIONS
In patients with cirrhosis and HCC, nutritional support to maintain and restore nutrition status, a targeted use of branched-chain amino acids and a guided physical exercise, should all be an integral part of the multidimensional assessment and tailored interventions.

Identifiants

pubmed: 34974449
pii: 000521741
doi: 10.1159/000521741
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

152-163

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Paolo Gallo (P)

Clinical Medicine and Hepatology Unit, Campus Bio-Medico University, Rome, Italy.

Marianna Silletta (M)

Medical Oncology Unit, Campus Bio-Medico University, Rome, Italy.

Antonio De Vincentis (A)

Internal Medicine Unit, Campus Bio-Medico University, Rome, Italy.

Federica Lo Prinzi (F)

Medical Oncology Unit, Campus Bio-Medico University, Rome, Italy.

Francesca Terracciani (F)

Clinical Medicine and Hepatology Unit, Campus Bio-Medico University, Rome, Italy.

Giuseppina Di Fazio (G)

Medical Oncology Unit, Campus Bio-Medico University, Rome, Italy.

Valentina Flagiello (V)

Clinical Medicine and Hepatology Unit, Campus Bio-Medico University, Rome, Italy.

Umberto Vespasiani Gentilucci (U)

Clinical Medicine and Hepatology Unit, Campus Bio-Medico University, Rome, Italy.

Raffaele Antonelli Incalzi (R)

Internal Medicine Unit, Campus Bio-Medico University, Rome, Italy.

Antonio Picardi (A)

Clinical Medicine and Hepatology Unit, Campus Bio-Medico University, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH